Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

Introduction Acquired resistance to TKI is an important unmet need in the management of
EGFR mutated lung cancer. Recent clinical trial IMPower150 suggested that combination …

Introduction EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor
(TKI) treatment. Because co-occurring genomic alterations might describe different …

Given the successful identification of epidermal growth factor receptor EGFR T790M, the
third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been …